80 results about "Follicle growth" patented technology

The present invention provides for a device comprising a scaffold composition, a bioactive composition and a bio-in-hibiting composition, wherein said bioactive and bio-inhibiting compositions are incorporated into or coated onto said scaffold composition, wherein said scaffold composition temporally supports survival and growth of resident follicles, migration and multiplication of stroma cells and spreading and organization of endothelial cells and new vessels wherein said bioactive composition regulates development of a resident follicle, formation of new blood vessels and chemoattraction and proliferation of stroma cells and wherein the bio-inhibiting composition regulates inhibition of the development of a second resident follicle. The presence of the bio-inhibiting composition within the scaffold is involved in the quiescence of the follicles in the primordial stage, which is important to restore fertility.

The invention discloses MiRNA apla-mir-25-42 related to follicular development of laying ducks and detection primers, inhibitors and application thereof, belonging to that field of genetic engineer technology. The nucleotide sequence of the MiRNA apla-mir-25-42 is shown in SEQ ID NO: 1. The research of the invention shows that the miRNA can regulate follicular development by targeting the TGFB2 gene, reduce the expression of the cell proliferation marker gene CyclinB2 and promote the expression of the cell apoptosis marker gene BCL2. The miRNA can be used as a marker to detect the proliferation and differentiation of granulosa cells in laying duck follicles. The technical scheme makes up the blank in the field, provides theoretical basis and scientific proof for analyzing the genetic mechanism of follicular development of laying ducks and is of great significance to study of the genetic nature of laying duck reproductive traits, improvement of the fecundity of laying duck and genetic assisted breeding of laying ducks.

The invention discloses a traditional Chinese medicinal hair growing fluid for treating alopecia seborrhoeica. The hair growing fluid comprises the following traditional Chinese medicinal raw materials in parts by weight: 90-110 parts of myrrh, 190-210 parts of asiatic bilberry leaf, 190-210 parts of folium artemisiae argyi, 190-210 parts of sweet wormwood herb, 140-160 parts of bunge corydalis herb, 190-210 parts of polygonum multiflorum, 190-210 parts of rhizoma cibotii, 190-210 parts of fructus psoraleae, 140-160 parts of drynaria total flavonoids, 190-210 parts of prepared rehmannia root, 140-160 parts of fructus rosae laevigatae, and 190-210 parts of astragalus membranaceus. The traditional Chinese medicinal hair growing fluid is prepared by grinding the raw materials into coarse powder according to the proportion, putting the coarse powder into a reaction kettle and decocting with 7 times amount of water to prepare the hair growing fluid. The traditional Chinese medicinal hair growing fluid has the effects of drying dampness, eliminating insects, disinfecting, killing mildew, resisting fungus and diminishing inflammation, has the functions nourishing blood and yin, replenishing essence and nourishing marrow, tonifying kidney and yang, dispelling blood to remove stasis, diminishing edema and promoting granulation, and promoting blood circulation, and can achieve the aims of eliminating chronic inflammation of hair follicle and scalp, killing lipophilic fungus and hair mite, clearing fomes in follicle, inhibiting over-secretion of androgen, and activating follicle growth.

The invention belongs to the technical field of biomedicines and particularly relates to a composition for improving premature ovarian failure, a preparation method therefor and application of the composition. According to the composition for improving the premature ovarian failure, provided by the invention, an in-vitro-constructed human uterine endometrium stem-cell cell membrane and a mesenchymal stem cell exosome are used in a compounded manner, thus, the development of ovarian follicles can be promoted, ovaries can be promoted to secrete an anti-Mullerian hormone, an ovarian follicle generator promoting level can be regulated, the apoptosis of ovarian cells can be inhibited, the adverse reserve function disease of the ovaries can be improved, the effect of improving primary or secondary premature ovarian failure is good, and thus, a new way of think is provided for clinically treating ovarian insufficiency and polycystic ovarian syndrome.

The invention provides 1ncRNA SFR1 as well as application thereof and a product and a method for regulating and controlling follicular development and relates to the technical field of biologics. Theinvention provides novel long-chain non-encoding RNA SFR1, wherein the 1ncRNA SFR1 is related to apoptosis of granular cells, and by regulating and controlling expression of 1ncRNA SFR1, correspondingregulation and control functions on channels, genes and hormones related to follicular development can be also achieved. Therefore, by adopting the 1ncRNA SFR1 and a corresponding product provided bythe invention, effective in-vivo / in-vitro regulation and control on follicular development can be achieved, and powerful guarantee can be provided for research on follicular development and physiology and biochemical functions. In addition, through the regulation and control functions of the 1ncRNA SFR1 on follicular development, the population fertility can be improved while excellent propertiesof genetic resources of mammals, particularly sheep, are maintained, and thus the economic benefits of breeding can be increased.

The invention provides an application of miRNA as a biomarker to prediction of IVF-ET outcome, and belongs to the technical field of biomedicines. According to the invention, a series of bioinformatics analysis tools are utilized to predict some candidate miRNAs which are used for targeted regulation of BDNF and are related to follicular development. FFs from mature follicles ( greater than 18 mm)or immature follicles smaller than 15 mm) are then collected, and whether the expression of the miRNAs is negatively correlated to the expression of the BDNF is evaluated. Finally, whether the miRNAscan become potential biomarkers for predicting the IVF-ET outcome or not is further researched. Therefore, two miRNAs, namely miR-103a-3p and miR-10a-5p, are finally screened out, the expression level of the miRNAs in the FF around specific oocyte can predict the outcome of the subsequent IVF treatment of the oocyte, and good practical application value is achieved.

The invention discloses an application of CTRP3 protein (C1qTNF related protein 3), and belongs to the fields of biotechnology and medicines. The CTRP3 protein provided by the invention can enhance the sensitivity of follicle to follicle stimulating hormone; and by identifying the expression of the CTRP3 protein in human and mouse ovaries, it indicates that the CTRP3 protein is autologous protein of the ovaries; therefore, the the CTRP3 protein can be safely developed and utilized as a drug. The effect of the CTRP3, as a follicle stimulating hormone sensitizer, on promoting follicle development is verified from three different levels, namely isolated ovarian tissue culture, isolated preantral follicle culture and living mesovarium injection, indicating that the CTRP3 protein, as the follicle stimulating hormone sensitizer, is effective on promoting preantral follicle and antral follicle development. The invention provides the effect and the mechanism of the CTRP3 participating in follicle development regulation and indicates that the CTRP3 protein, as the follicle stimulating hormone sensitizer, is applicable to the treatment of female ovarian hypoplasia diseases, so that the effect of the follicle stimulating hormone on the development of the follicle is enhanced.

The invention primarily relates to the use of somatostatin or one of the agonistic analogs thereof for producing a medicament serving to regulate the ovarian follicular reserve and, in particular, to reduce the depletion of the ovarian follicular reserve over time in non-menopausal women or to the use of an antagonistic analog of somatostatin for producing a medicament serving to accelerate the start of growing of quiescent follicles in non-menopausal women. The invention also relates to in vitro applications of somatostatin and of agonistic and antagonistic analogs thereof.

The invention discloses a laying duck follicle growth-associated miRNA alpha-mir-145 and detecting primer, inhibitor and application thereof and belongs to the technical field of genetic engineering.The nucleotide sequence of the laying duck follicle growth-associated miRNA alpha-mir-145 is shown as SED ID NO: 1. Research shows that the laying duck follicle growth-associated miRNA alpha-mir-145 can regulate follicle growth through targeted PIK3CA genes, reduce expression of a cell proliferation marker gene CyclinB2 and enhance expression of a cell apoptosis marker gene BCL2. The laying duck follicle growth-associated miRNA alpha-mir-145 can serve as a marker for detecting proliferation of laying duck follicular cells, thereby filling the gap in the field, providing a theoretical basis anda scientific basis for analysis on the genetic mechanism of laying duck follicle growth and being of great significance to researching the genetic nature of duck reproduction traits, improving the reproductivity of laying ducks and achieving assisted genetic breeding.

The invention discloses application of nicotinic acid derivates in the preparation of medicaments for promoting follicular development and maintaining ovarian functions. Experiment proves that the nicotinic acid derivates can promote follicular growth in the ovary, promote hormonogenesis and endometrial growth and enable women to form a regular period. The derivates have special treatment effects on promoting follicular development and maturing, treating ovarian hypofunction, recovering period and reducing climacteric symptoms. The invention compensates for the defects of the existing medicaments, and provides a new method for treating ovarian diseases, which is high in efficiency, convenient to use and low in cost.

The invention provides a culture method for in-vitro human oocyte preantral follicles. The culture method is characterized by comprising the following specific steps of: 1) unfreezing the in-vitro human oocytes placed in frozen protecting solution containing cane sugar and propylene glycol and subjected to liquid nitrogen low-temperature storage, and then reviving and culturing; and 2) separating and extracting the in-vitro human oocytes obtained by reviving and culturing, then placing the in-vitro human oocytes in nutrient solution containing follicle-stimulating hormone (FSH), and performing preantral culture, wherein the culture for in-vitro human oocyte preantral follicles needs the support of FSH, and FSH can be used for promoting the growth of the follicles, increasing the survival time of the follicles, promoting the proliferation of granular cells, and promoting the maturation of the oocytes, as well as is an important factor for regulating and controlling the growth and development of the follicles; and trichostatin A can be used for effectively inhibiting the proliferation of tumour cells, regulating and controlling the progress of a cell cycle and then inducing the apoptosis of tumour cells, thus ensuring the survival quality of the cells. The method has important significance on researches in the aspect of test-tube babies.

The invention belongs to the field of traditional Chinese medicines, and provides a traditional Chinese medicine preparation for treating infertility caused by ovulation failure. The traditional Chinese medicine preparation mainly comprises a formula capable of invigorating the kidney and replenishing essence, a formula capable of reinforcing the kidney and activating blood, and a formula capableof accelerating corpus luteum, wherein the formula capable of invigorating the kidney and replenishing essence comprises the following raw material ingredients: 15-24 g of radix rehmanniae praeparata,15-30 g of rhizoma dioscoreae, 12-18 g of fructus corni, 15-20 g of fructus lycii, 15-30 g of herba epimedii, 15-30 g of semen cuscutae, 9-12 g of vinegar-processed testudinis carapax, 12-24 g of herba cistanches, 9-12 g of cornu cervi degelatinatum, 12-18 g of radix angelicae sinensis, 9-15 g of parched paeoniae alba radix, 9-15 g of parched atractylodis macrocephalae rhizome and 6-12 g of endothelium corneum gigeriae galli. According to a rule of mutual transformation between yin and yang as well as qi and blood replenishment and deficiency change during each period of menstruation, follicle development and ovulation can be accelerated, the ovulation rate and the pregnancy rate of the anovulatory infertility can be improved, a clinical curative effect is exact, a pregnancy rate is high,and an ovulation failure problem is solved fundamentally.

The present invention relates to improved assisted reproductive technology using highly purified menotropin (HP-hMG) to stimulate follicle development in controlled ovarian stimulation, particularly in women at risk of a high ovarian response to controlled ovarian stimulation.

The invention discloses a sheep ovarian granular cell separation, culture and identification method, and belongs to the technical field of animal cell culture. Ovarian granular cells are obtained through special treatment modes of collection, disinfection, cutting and the like. The method has the advantages of being simple, convenient, labor-saving, low in pollution rate, high in follicular fluid obtaining rate and the like, and a foundation is laid for research on development of ovarian granular cells, oocytes and follicles.

Methods are provided for activating dormant ovarian primordial follicles in a mammal to promote development to preovulatory follicles.

A method of inducing young primates to obtain gonad gametes is disclosed. The method includes administering a female young primate with gonadotropin-releasing hormone or an analogue thereof, performing combined administration of gonadotropin, and inducing follicular development to obtain mature oocytes that are female gametes; administering a male young primate with gonadotropin, performing combined administration of gonadotropin-releasing hormone or an analogue thereof, and inducing testis spermatogenesis to obtain sperms that are female gametes; and subjecting the obtained female gametes and male gametes to fertilization, and allowing fertilized eggs to develop until blastulas or a filial generation. A hormone combination is adopted by the method to promote induction of young primate sexual prematurity, thus obtaining the gonad gametes in advance, significantly shortening the generation period of primates, and accelerating offspring breeding. The method can achieve large-scale expanding propagation of the young primates, shorten the generation period, reduce the cost, and provide experience references for germplasm preservation of precious and endangered animal species and rapid animal propagation through gene editing.

Methods of preparing ovarian tissue for primordial follicle growth are presented comprising the steps: providing an ovarian tissue sample comprising cortical tissue and stromal tissue; removing damaged tissue from the ovarian tissue sample where present; removing excess stromal tissue from the ovarian tissue sample where present; and then mechanically stretching the ovarian tissue sample along at least one dimension of the ovarian tissue sample, such that the size of the ovarian tissue sample along the at least one dimension is increased by at least 10%. Methods of growing viable oocyte in vitro, and methods of preparing individual ovarian follicles for growth are also presented.

The invention belongs to the technical field of embryo transplantation and relates to a control method for synchronization of menstrual cycles of a donor mare and a receptor mare. The control method comprises the steps of respectively examining the donor mare and the receptor mare more than once every day, and recording dynamic information of oestrus states, follicle growth states and ovulation time; making a form for the dynamic information to track, observe and record menstrual cycle information of the maria; using prostaglandin on the donor mare and the receptor mare to enable the maria to be in oestrum according to difference with the dynamic information; measuring the diameters of follicles according to the dynamic information and images after the maria are in oestrum; finally utilizing human chorionic gonadotropin to promote ovulation and generate corpus luteum according to physiological difference; and achieving synchronization of menstrual cycles of the donor mare and the receptor mare. The control method is simple in principle, easily controllable in process, accurate in control, high in efficiency and good in effect.

The invention discloses an application of chi-miR-450-5p as an miRNA marker for maturation of goat follicles. The chi-miR-450-5p provided by the invention can reflect the maturation of goat follicles,and has reliability, universality and repeatability as a follicle development marker. The invention also discloses a test kit for detecting the development condition of the goat follicles. Accordingto the invention, through separation of follicle granulosa cells, the expression mode of the chi-miR-450-5p in dominant follicles and small follicle granulosa cells is verified, and a basis is provided for perfecting a goat follicle growth and development, ovulation gene regulation and non-coding regulation network.

The invention discloses recombinant human growth hormone and the application thereof in promoting follicular development, belongs to the field of protein drugs, and relates to growth hormone (GH).The recombinant human growth hormone is suitable for promoting follicular development and can increase the rate of pregnancy.The invention further relates to a long-acting pharmaceutic preparation of GH and the application thereof.

A method of treating infertility disorders by 1) administering an LH-RH antagonist, preferably Cetrorelix, in amounts to selectively suppress endogenous LH but not FSH secretion and 2) inducing follicle growth by administration of exogenous gonadotropin. The selective suppression OF LH allows FSH secretion to be at natural levelS thereby not affecting individual estrogen development. The LH-RH antagonist can be given as a single or dual subcutaneous dose in the range of 1 mg to 10 mg, preferably 2 mg-6 mg. In multiple dosing-posology, LH-RH antagonist can be administered subcutaneously in an amount in the range of 0.1 to 0.5 mg of LH-RH antagonist / day. LH-RH antagonist is applied starting cycle day 1 to 10, preferably on day 4 to 8, and ovulation can be induced between day 9 and 20 of the menstruation cycle by administering rec. LH, native LH-RH, LH-RH agonist or by HCG. In addition rec. LH, native LH-RH or LH-RH agonist can be given to avoid hyperstimulation syndrome and native LH-RH or a LH-RH agonist can be administered to avoid luteal phase stimulation by neutralizing the negative effects of HCG.

The invention belongs to the technical field of cosmetics, and discloses a silicon oil free shampoo capable of preventing alopecia. The shampoo is prepared from the following raw materials in parts by weight: 9-13 parts of dodecyl polyglucoside, 4-9 parts of sodium olivoyl glutamate, 1-5 parts of coconut oil monoisopropanolamine, 0.5-2.5 parts of polyquaternary ammonium salt-10, 0.1-0.9 part of guar hydroxypropyltrimonium chloride, 1-4 parts of raspberry seed oil, 2-5 parts of a poterium officinale root extract, 0.1-0.6 part of a pyrus cydonia extract, 2-6 parts of a paniculate swallowwort root extract, 0.2-0.7 part of citric acid, 0.1-0.5 part of ethylenediaminetetraacetic acid, 0.1-0.4 part of hydroxypropyl methyl cellulose, 0.1-0.3 part of kathon, 0.2-0.5 part of essence and 40-60 parts of water. The shampoo provided by the invention, when used for cleaning hair, can stimulate follicle growth and activate scalp cells, and in addition, the shampoo can enhance blood circulation in scalp; the shampoo has functions of promoting circulation of blood and qi, treating alopecia and controlling oil; and specifically, the shampoo has a significant curative effect on seborrheic alopecia.

The invention provides application of 11beta-hydroxysteroid dehydrogenase 1 (11beta-HSD1) inhibitor in preparation of a drug for treating polycystic ovarian syndrome (PCOS). The molecular formula of the 11 beta-HSD1 is as follows: C17H21ClN4O3S2 and the structural formula is shown in the specification. According to the invention, the 11 beta-HSD1 selective inhibitor can inhibit the activity and expression of 11 beta-HSD1 in the ovary part of a PCOS rat and a phenomenon that the concentration of ovarian local cortisol of a PCOS rat is increased is avoided. Meanwhile, with the 11 beta-HSD1 selective inhibitor, the peripheral insulin resistance of the PCOS rat can be improved and ovulation dysfunction such as follicle growth and development and hormone synthesis can be treated. Therefore, the11 beta-HSD1 selective inhibitor has important significance in treating metabolic disorder and reproductive dysfunction of PCOS.

The invention discloses a serum-free culture solution for in-vitro culture of sheep ovarian cortex tissue. The culture solution comprises a basic culture solution and an additive, wherein the basic culture medium is a mixed solution of alpha-MEM and DMEM; the additive comprises the following components: 3-10 micrograms / mL bovine serum albumin, 0.10-0.50mM sodium pyruvate, 1-5mM glutamine, 1-5mM hypoxanthine, 3-10 micrograms / mL insulin, 1-5 micrograms / mL transferrin, 2-8 nanograms / mL sodium selenite, 10-200 micrograms / mL VC, 50-200IU / mL penicillin and 50-200IU / mL streptomycin, and the pH valueis 6.9-7.5. Through the synergistic effect of the components, the proliferation speed of interstitial cells is inhibited, the proliferation of granular cells is promoted, the defect that the three-dimensional environment of original follicle development cannot be maintained due to tissue collapse caused by excessive proliferation of the interstitial cells in the culture process of the ovarian cortex tissue is overcome, the growth and development condition and survival time of original follicles in the ovarian cortex tissue in vitro are effectively improved, meanwhile, the influence of unknowncomponents in serum on research is avoided, and the serum-free culture solution has a good application prospect.

The present technology provides for methods for generation and isolation of granulosa cells and / or granulosa cell precursors from multi-potent cells, wherein the granulosa cells and / or granulosa cell precursors are useful in methods for growth and maturation of follicles or follicle-like structures. Additionally, the present technology also provides for methods of increasing steroidal hormones in a subject in need thereof.

The invention relates to a follicle development prediction system in hyper-ovulation therapy based on artificial intelligence technology. An artificial intelligence function model system is obtained through autonomous learning and training by combining a gynecological endocrine related theory from the perspective of artificial intelligence and taking clinical data of previous patient diagnosis and treatment as a research object; clinical doctors are assisted in clinical pre-judgment and clinical error early warning and correction, and the safety, accuracy, controllability and efficiency of clinical diagnosis and treatment are improved; a new perspective is provided for research on clinical management of COH patients in reproductive medicine, and the limitations of insufficient artificial clinical diagnosis and treatment experience and limited prediction and pre-judgment ability in the hyper-ovulation therapy process are improved; fine and standardized research on the hyper-ovulation medication dosage is promoted, an early warning value is set for OHSS case data generated by a wrong medication scheme, and a theoretical basis is provided for early warning correction through a computer language; and the diagnosis and treatment efficiency of clinicians is optimized, the COH medical risk is reduced, the egg obtaining outcome cost performance is improved, and the medical cost is saved.

The invention provides a superovulation polyvinylpyrrolidone FSH composite slow-release injection for sika deer. Four substances, such as FSH, acidic xylosidase, cellulase and gentamicin, are uniformly dispersed in polyvinylpyrrolidone so as to form a slow release agent; and according to a synergistic effect of medicines such as FSH, acidic xylosidase, cellulose, gentamicin and the like, target substances and indirectly produced nutrient substances can continuously and uniformly act on ovary cells so as to promote follicle growth and maturity; and therefore, a good effect on superovulation is achieved, and the mature ovum is high in quality. According to the dosage form, stress reaction is reduced by intravenous injection, and intense struggling caused by pain is alleviated.

The invention provide a 3D printed artificial ovarium biological stent capable of activating an original ovarian follicle. According to the 3D printed artificial ovarium biological stent, a 3D printing technology is utilized to mix an original ovarian follicle activating agent and hormones and growth factors which can promote the developing of the ovarian follicle into a stent material to be molded through printing, an ovarian cortex fragment which contains the original ovarian follicle is transplanted, after the cortex fragment is transplanted back to the body, the cortex fragment can achievebetter stent protection and more diversified nutrient supplying, the biological stent is gradually degraded in the body to sustainably release the ovarian follicle activating agent, and therefore theoriginal ovarian follicle is sustainably activated. The stent has the advantages that the in vitro activating time of the original ovarian follicle is greatly reduced, a novel researching tool is provided for an revealing an original ovarian follicle activating mechanism, the waiting time of the patient is reduced on the basis that secondary surgery is avoided, and a novel choice is provided forthe clinical treatment of premature ovarian failure and an assisted reproduction technology; after the ovarian follicle is activated, a large number of hormones are secreted to regulate the secretionin the body, and a novel researching direction is provided for improving comprehensive symptoms of menopause and ageing slowing.